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BACKGROUND
Whether it is possible to reduce the intensity of treatment in early (stage I or II) 
Hodgkin’s lymphoma with a favorable prognosis remains unclear. We therefore con-
ducted a multicenter, randomized trial comparing four treatment groups consisting 
of a combination chemotherapy regimen of two different intensities followed by 
involved-field radiation therapy at two different dose levels.
METHODS
We randomly assigned 1370 patients with newly diagnosed early-stage Hodgkin’s lym-
phoma with a favorable prognosis to one of four treatment groups: four cycles of 
doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by 30 Gy of 
radiation therapy (group 1), four cycles of ABVD followed by 20 Gy of radiation 
therapy (group 2), two cycles of ABVD followed by 30 Gy of radiation therapy (group 3), 
or two cycles of ABVD followed by 20 Gy of radiation therapy (group 4). The primary 
end point was freedom from treatment failure; secondary end points included effi-
cacy and toxicity of treatment.
RESULTS
The two chemotherapy regimens did not differ significantly with respect to freedom 
from treatment failure (P = 0.39) or overall survival (P = 0.61). At 5 years, the rates of 
freedom from treatment failure were 93.0% (95% confidence interval [CI], 90.5 to 
94.8) with the four-cycle ABVD regimen and 91.1% (95% CI, 88.3 to 93.2) with the 
two-cycle regimen. When the effects of 20-Gy and 30-Gy doses of radiation therapy 
were compared, there were also no significant differences in freedom from treat-
ment failure (P = 1.00) or overall survival (P = 0.61). Adverse events and acute toxic 
effects of treatment were most common in the patients who received four cycles of 
ABVD and 30 Gy of radiation therapy (group 1). 
CONCLUSIONS
In patients with early-stage Hodgkin’s lymphoma and a favorable prognosis, treat-
ment with two cycles of ABVD followed by 20 Gy of involved-field radiation therapy 
is as effective as, and less toxic than, four cycles of ABVD followed by 30 Gy of in-
volved-field radiation therapy. Long-term effects of these treatments have not yet 
been fully assessed. (Funded by the Deutsche Krebshilfe and the Swiss Federal 
Government; ClinicalTrials.gov number, NCT00265018.)
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Radiation therapy was the original mainstay of treatment for patients who had early-stage Hodgkin’s lymphoma with a 
favorable prognosis. With the use of such tech-
niques as extended-field radiation therapy and to-
tal lymphoid irradiation, more than 80% of pa-
tients with localized disease became long-term 
survivors. However, the relapse rate with radia-
tion therapy alone ranged from 20 to 40%,1-3 and 
extended-field radiation therapy and total lymphoid 
irradiation were associated with the occurrence 
of secondary solid tumors.4-8 The integration of a 
chemotherapy regimen consisting of doxorubicin, 
bleomycin, vinblastine, and dacarbazine (ABVD)9 
with radiation therapy resulted in greater efficacy 
and allowed the radiation field and dose to be 
reduced, leading to widespread use of the com-
bined approaches in patients with early-stage 
Hodgkin’s lymphoma and a favorable progno-
sis.10,11 Four cycles of ABVD followed by 30 Gy of 
involved-field radiation therapy is now regarded 
as the standard of care by many groups.11-14 The 
use of chemotherapy alone has been considered 
as a potential alternative approach but remains 
controversial.15-19
Whether the number of treatment cycles and 
the radiation dose can be reduced in patients with 
early-stage Hodgkin’s lymphoma and a favorable 
prognosis remains unclear. In an attempt to re-
duce the toxic effects of treatment while retain-
ing full control of the cancer, the German Hodg-
kin Study Group (GHSG) in 1998 initiated a 
prospective, randomized, multicenter study (HD10) 
in which four cycles of ABVD chemotherapy were 
compared with two cycles of ABVD, and 30 Gy 
of involved-field radiation therapy was compared 
with 20 Gy of involved-field radiation therapy in 
patients receiving either of the two chemotherapy 
regimens.
Me thods
Study Patients
We enrolled patients who had newly diagnosed 
Hodgkin’s lymphoma in clinical stage I or II, as 
confirmed on histologic examination, with no 
clinical risk factors. Patients were eligible if they 
were between 16 and 75 years of age, had not 
been treated previously for Hodgkin’s lymphoma, 
and were free of concurrent disease. (Details re-
garding the definitions of clinical risk factors and 
full descriptions of the inclusion and exclusion 
criteria are provided in the Supplementary Ap-
pendix, available with the full text of this article 
at NEJM.org.)
Study Design
HD10 was a multicenter, randomized study of 
four different treatment regimens in patients with 
early-stage Hodgkin’s lymphoma and a favorable 
diagnosis. Patients were recruited and treated at 
329 hospitals and outpatient practices in Germa-
ny, Switzerland, the Netherlands, the Czech Re-
public, and Austria. After clinical staging had been 
completed and written informed consent ob-
tained, patients were registered at the GHSG cen-
tral trial office by telephone and then randomly 
assigned in a 1:1:1:1 ratio to one of four treat-
ment groups: group 1 received four cycles of ABVD 
followed by 30 Gy of involved-field radiation ther-
apy; group 2 received four cycles of ABVD fol-
lowed by 20 Gy of involved-field radiation thera-
py; group 3 received two cycles of ABVD followed 
by 30 Gy of involved-field radiation therapy; and 
group 4 received two cycles of ABVD followed by 
20 Gy of involved-field radiation therapy.
Stratification factors included trial center and 
prognostic factors that might influence the pri-
mary end point, such as age (<50 vs. ≥50 years), 
systemic symptoms, supradiaphragmatic or in-
fradiaphragmatic disease, and albumin level (<4 
vs. ≥4 g per deciliter). A 2-by-2 factorial design 
was chosen: for the chemotherapy comparison, the 
results in groups 1 and 2, which received four 
cycles of ABVD, were pooled, as were the results 
in groups 3 and 4, which received two cycles of 
ABVD. Similarly, for the radiation therapy com-
parison, the results in groups 1 and 3, which re-
ceived the 30-Gy dose of involved-field radiation 
therapy, were pooled and compared with the re-
sults in groups 2 and 4, which received the 20-Gy 
dose of involved-field radiation therapy.
The HD10 protocol was designed by the GHSG 
steering committee and approved by the ethics 
committees of the participating centers. The study 
was performed in accordance with the protocol. 
An independent data and safety monitoring com-
mittee monitored the patients’ safety and the ef-
ficacy of treatment throughout the 5-year study 
period. The GHSG central trial office was respon-
sible for data collection, data management, and 
statistical analyses, as well as for internal presen-
tations of results to the GHSG chairman and par-
ticipating centers. The GHSG steering committee 
and chair decided to submit the results of the fi-
nal analysis for publication. All authors contrib-
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uted to the interpretation of the results and vouch 
for the accuracy and completeness of the data. The 
GHSG chair wrote the first draft of the manuscript 
and was supported by the lead statistician. There 
was no commercial involvement in this study and 
no financial support from industry.
Chemotherapy
ABVD was administered on days 1 and 15 in 
monthly cycles, at the following standard doses: 
doxorubicin, 25 mg per square meter of body-
surface area; bleomycin, 10 mg per square meter; 
vinblastine, 6 mg per square meter; and dacarba-
zine, 375 mg per square meter. If the white-cell 
count was less than 2500 per cubic millimeter or 
the platelet count was less than 80,000 per cubic 
millimeter on a day when chemotherapy was sched-
uled to be administered, treatment was postponed 
until normal levels were achieved. Granulocyte 
colony-stimulating factor was given if clinically 
indicated.
Radiation therapy
Before treatment, all sites of disease were defined 
and documented by the treating medical oncolo-
gist and radiation oncologist. A central panel of 
experts in radiation oncology then planned in-
volved-field radiation therapy as defined in the 
study protocol according to treatment group and, 
if necessary, revised the initial staging. The rec-
1370 Patients underwent randomization
346 Were assigned
to group 1
(4×ABVD + 30 Gy IFRT)
180 Were excluded
30 Did not have histologic
features of Hodgkin’s
lymphoma
133 Had wrong initial staging
16 Did not meet other inclusion
criteria
1 Withdrew before start of
therapy
298 in group 1 were
included in analysis
340 Were assigned
to group 2
(4×ABVD + 20 Gy IFRT)
298 in group 2 were
included in analysis
299 in group 4 were
included in analysis
295 in group 3 were
included in analysis
596 in groups 1 and 2 were included in
analysis for CT comparison (4×ABVD)
 575 in groups 1 and 3 were included in
analysis for RT comparison (30 Gy)
594 in groups 3 and 4 were included in
analysis for CT comparison (2×ABVD)
588 in groups 2 and 4 were included in
analysis for RT comparison (20 Gy)
341 Were assigned
to group 3
(2×ABVD + 30 Gy IFRT)
343 Were assigned to
group 4
(2×ABVD + 20 Gy IFRT)
1190 Were included in analysis for 4-group comparison
1190 Were included in analysis for ABVD comparison
27 Withdrew before RT
12 Were in group 1
6 Were in group 2
6 Were in group 3
3 Were in group 4
1163 Were included in analysis for IFRT comparison
Figure 1. Numbers of Patients Randomly Assigned to Treatment Groups and Included in Analyses.
ABVD denotes doxorubicin, bleomycin, vinblastine, and dacarbazine, and IFRT involved-field radiation therapy.
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ommended interval between completion of the ABVD 
regimen and the start of radiation therapy was 4 to 
6 weeks. Patients received either 30 Gy or 20 Gy of 
involved-field radiation therapy in single fractions 
of 1.8 to 2.0 Gy administered five times weekly.
Study End Points
The primary efficacy end point was freedom from 
treatment failure. Overall survival, progression-free 
survival, complete response, and treatment toxicity 
were secondary end points. Definitions of the study 
end points are provided in the Supplementary Ap-
pendix.
Statistical Analysis
Proof of the noninferiority of the less intensive treat-
ment, as compared with the standard treatment of 
four cycles of ABVD plus 30 Gy of involved-field 
radiation therapy, with respect to freedom from 
treatment failure at 5 years was the goal for both 
chemotherapy and radiation therapy. The noninfe-
riority margin was defined as 7% in the study pro-
tocol. This led to the following two hypotheses: for 
chemotherapy, the 5-year rate of freedom from treat-
ment failure in the two pooled groups assigned to 
two cycles of ABVD would be less than 7% below 
the rate in the two pooled groups assigned to four 
cycles, and for radiation therapy, the 5-year rate of 
freedom from treatment failure in the two pooled 
groups assigned to 20 Gy of involved-field radiation 
therapy would be less than 7% below the rate in the 
two pooled groups assigned to 30 Gy.
Survival rates for the four groups were compared 
with the use of the Kaplan–Meier method as well as 
stratified Cox regression analyses for hazard ratios 
(i.e., the chemotherapy comparison was stratified 
according to the radiation therapy assignment and 
vice versa), whereas outcomes and toxicity rates were 
compared with the use of Fisher’s exact test. Tests 
of the hypotheses were performed according to the 
intention-to-treat principle and also on the basis of 
the treatment actually received. Subgroup analyses 
were not prespecified in the statistical-analysis 
plan, but we performed post hoc sensitivity analy-
ses that excluded patients with nodular lympho-
cyte-predominant Hodgkin’s lymphoma. The results 
of these sensitivity analyses are presented in the 
Supplementary Appendix.
In addition, to estimate the combined effect of 
reduced chemotherapy and reduced radiation ther-
apy, we compared group 1, which received the most 
intensive therapy, with group 4, which received the D
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least intensive therapy. To detect a possible in-
fluence of prognostic factors or interactions be-
tween the effects of chemotherapy and those of 
radiation therapy, multivariate Cox regression 
analyses were specified in the protocol and per-
formed as sensitivity analyses on the same data 
sets for comparing the two chemotherapy regi-
mens and the two radiation therapy regimens.
R esult s
Patients
From May 1998 through January 2003, a total of 
1370 patients were recruited and randomly as-
signed to treatment centrally. A total of 180 pa-
tients were excluded from all analyses: 30 because 
the reference histologic findings did not confirm 
Hodgkin’s lymphoma, 133 because of incorrect 
initial staging, 16 because they did not meet oth-
er inclusion criteria, and 1 who met the inclusion 
criteria but could not subsequently be contacted 
(Fig. 1).
The baseline characteristics of the study pa-
tients are shown in Table 1. No significant dif-
ferences were noted among the treatment groups 
for any of the characteristics shown. The median 
age of patients at randomization was 36 years 
(range, 16 to 75), and 61.0% were male; 30.3% 
had stage IA disease, 2.0% had stage IB, 62.0% 
had stage IIA, and 5.5% had stage IIB. (Informa-
tion on stage of disease was missing for one pa-
tient in group 2.) The most frequent subtype 
diagnosed by the pathology reference panel was 
mixed cellularity (40.2%), and 8.1% of patients 
had infradiaphragmatic disease.
The main (intention-to-treat) analysis set for 
the initial chemotherapy comparison (CT1) com-
prised 1190 patients: 596 patients were randomly 
assigned to four cycles of ABVD and 594 to two 
cycles. Of these patients, 36 changed chemother-
apy group or had major protocol violations; che-
motherapy was not documented for 10 patients. 
The per-protocol analysis set for the chemothera-
py comparison (CT2) therefore comprised 1144 
patients (571 randomly assigned to four cycles of 
ABVD and 573 to two cycles). The main (inten-
tion-to-treat) analysis set for the radiation ther-
apy comparison (RT1) included 1163 patients: 
575 patients were randomly assigned to 30 Gy of 
involved-field radiation therapy and 588 to 20 Gy 
of involved-field radiation therapy. Of these pa-
tients, 33 had a change in the radiation therapy 
dose or had major protocol violations; radiation 
therapy documentation was missing for 17 pa-
tients. The per-protocol analysis set for the radia-
tion therapy comparison included 1113 patients 
(557 in the 30-Gy groups and 556 in the 20-Gy 
groups). There were more protocol violations 
and group changes in the groups that received 
20 Gy of involved-field radiation therapy than in 
those that received 30 Gy (P = 0.05). However, 
since the per protocol analysis and the intention-
to-treat analysis had similar results, these im-
balances did not affect the final conclusions.
Adverse Events
Toxicity of Treatment
Acute toxicity during chemotherapy was more fre-
quent in patients who received four cycles of 
ABVD than in those who received two cycles (Ta-
ble 2). Overall, 51.7% of the patients who received 
four cycles of ABVD had at least one instance of 
severe toxicity (grade III or IV) as compared with 
33.2% of those who received two cycles (P<0.001). 
The most frequent events were hair loss (in 28.1% 
of patients receiving four cycles vs. 15.2% of those 
receiving two cycles) and hematologic toxic ef-
fects (24.0% vs. 15.0%). Infections were also more 
common with four cycles of ABVD than with 
two cycles (5.1% vs. 1.7%). Treatment-related 
deaths occurred in six patients treated with four 
cycles of ABVD (two died from pulmonary fi-
brosis, two from sepsis, one from pneumonia, 
and one from an unspecified cause) and in one 
patient treated with two cycles (from pulmonary 
fibrosis).
Severe toxicity (grade III or IV) was observed 
more often among the patients treated with 30 Gy 
of involved-field radiation therapy than among 
those who received 20 Gy (8.7% vs. 2.9%, 
P<0.001).
Secondary Neoplasia
Over a median follow-up period of 7.5 years (90 
months), secondary cancers were diagnosed in a 
total of 55 patients (4.6%): 38 solid tumors, 15 cas-
es of non-Hodgkin’s lymphoma, and 2 cases of 
acute myeloid leukemia. There were no significant 
differences in the occurrence of secondary can-
cers among the four treatment groups (P = 0.59), 
the pooled chemotherapy groups (P = 0.89), or the 
pooled radiation therapy groups (P = 0.34).
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Deaths
A total of 57 patients (4.8%) died during the fol-
low-up period. The most frequent causes of death 
were secondary neoplasia (in 11), Hodgkin’s lym-
phoma (in 10), cardiovascular events (in 9), toxic-
ity of primary therapy (in 7), and toxicity of sal-
vage therapy (in 5, all after having received two 
cycles of ABVD). No difference in mortality was 
noted among the four groups or between the com-
bined chemotherapy groups and the combined 
radiation therapy groups (Table 2).
Disease Control and Survival
Final treatment outcomes were as follows: 1150 
of 1190 patients (96.6%) had a complete remission, 
8 (0.7%) had a partial remission, and 8 (0.7%) did 
not have a response (2 had no change and 6 had 
progression of disease during treatment). (Re-
sponse criteria are described in the Supplemen-
tary Appendix.) For 24 patients (2.0%), the treat-
ment outcome was unclear. The relapse rate was 
6.0% (71 of 1190 patients). No significant differ-
ences were seen in rates of remission, progres-
sion, or relapse among the four treatment groups 
or between the combined chemotherapy groups 
and the combined radiation therapy groups.
The rates of freedom from treatment failure in 
the whole intention-to-treat analysis set of 1190 
patients were estimated to be 92.0% (95% confi-
dence interval [CI], 90.2 to 93.5) at 5 years and 
87.1% (95% CI, 84.5 to 89.3) at 8 years. The over-
all survival rates for all 1190 patients were esti-
mated to be 96.8% (95% CI, 95.7 to 97.7) at 5 years 
and 94.5% (95% CI, 92.8 to 95.8) at 8 years 
(Table 3). For the same patients, the rate of pro-
gression-free survival was estimated to be 92.4% 
(95% CI, 90.6 to 93.8) at 5 years and 87.6% (95% 
CI, 85.0 to 89.7) at 8 years.
Chemotherapy Comparison
In the intention-to-treat analysis, the median ob-
servation time for the primary end point, freedom 
from treatment failure, was identical in the two 
chemotherapy groups (79 months). The rate of free-
dom from treatment failure at 5 years was 93.0% 
with four cycles of ABVD (95% CI, 90.5 to 94.8) 
and 91.1% with two cycles (95% CI, 88.3 to 93.2) 
(Table 3). On the basis of the stratified Cox re-
gression analysis, the hazard ratio for treatment 
failure with two cycles of ABVD as compared 
with four cycles was 1.17 (95% CI, 0.82 to 1.67). 
The 5-year estimated group difference (two cy-
cles vs. four cycles) was −1.9 percentage points 
(95% CI, −5.2 to 1.4). The sensitivity analysis, 
based on treatment received per protocol, showed 
a 5-year estimated group difference of −2.3 per-
centage points (95% CI, −5.6 to 2.9). On the basis 
of these results, the predefined 7% inferiority of 
two cycles of ABVD plus radiation therapy can be 
excluded for the primary end point, freedom 
from treatment failure. The intention-to-treat 
analysis showed no significant differences be-
tween the two chemotherapy groups for the sec-
ondary end points of overall survival (P = 0.93; 
hazard ratio for death, 1.02 [95% CI, 0.61 to 
1.72]) and progression-free survival (P = 0.28; 
hazard ratio for progression, relapse, or death 
from any cause, 1.22 [95% CI, 0.85 to 1.77]).
Radiation therapy Comparison
In the intention-to-treat analysis of radiation ther-
apy, the median observation time for the primary 
end point, freedom from treatment failure, was 
similar in the two groups: 77 months with 20 Gy 
and 80 months with 30 Gy. The rate of freedom 
from treatment failure at 5 years was 93.4% (95% 
Figure 2 (facing page). Freedom from Treatment Failure 
and Overall Survival.
Two pooled treatment  groups were compared with re-
spect to chemotherapy regimens (groups 1 and 2 vs. 
groups 3 and 4) (Panel A) and radiation therapy doses 
(groups 1 and 3 vs. groups 2 and 4) (Panel B). Groups 
1 and 4 were also compared (Panel C). Group differ-
ences with respect to freedom from treatment failure 
and overall survival at 5 years were estimated on the 
basis of Kaplan–Meier analyses, and hazard ratios were 
calculated with the use of Cox regression analysis (i.e., 
the comparison of the chemotherapy groups was strati-
fied according to radiation therapy group, and vice ver-
sa). (For definitions of study end points, see the Sup-
plementary Appendix, available with the full text of this 
article at NEJM.org.) Data for all patients were analyzed 
on the basis of the randomly assigned treatment 
groups (intention-to-treat principle). Data for overall 
survival were censored on the date when the informa-
tion was last obtained; when the information lag ex-
ceeded 2 years, data on survival were obtained from 
registries, whenever possible. The median observation 
period for freedom from treatment failure was 79 
months and that for overall survival was 91 months. 
The main analysis for the chemotherapy comparison  
included 1190 eligible patients who received at least  
1 dose of the assigned study treatment. According to 
the protocol, 27 patients whose disease progressed or 
whose chemotherapy was discontinued before the start 
of radiation therapy were excluded from the main analy-
sis for the radiation therapy comparison. (For methods 
and results of the sensitivity analyses, see the Supple-
mentary Appendix.)
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CI, 91.0 to 95.2) in the 30-Gy group and 92.9% 
(95% CI, 90.4 to 94.8) in the 20-Gy group (Table 3). 
The hazard ratio for treatment failure with 20 Gy 
as compared with 30 Gy was 1.00 (95% CI, 0.68 to 
1.47). The 5-year estimated group difference (20 Gy 
vs. 30 Gy) was −0.5 percentage points (95% CI, 
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−3.6 to 2.6). The sensitivity analysis based on ther-
apy received showed a 5-year estimated group dif-
ference of −0.2 percentage points (95% CI, −3.3 to 
2.8). Thus, the predefined 7% inferiority of che-
motherapy plus 20 Gy of radiation therapy can be 
excluded for the primary end point (freedom from 
treatment failure). The intention-to-treat analysis 
showed no significant differences between the 
radiation therapy groups for the secondary end 
points of overall survival (P = 0.61; hazard ratio 
for death, 0.86 [95% CI, 0.49 to 1.53]) and pro-
gression-free survival (P = 0.98; hazard ratio for 
progression, relapse, or death from any cause, 1.01 
[95% CI, 0.68 to 1.48]). Overall, the rates of free-
dom from treatment failure might appear to be 
higher than those in a pure intention-to-treat 
analysis, since patients who dropped out before 
radiation therapy were excluded from this analy-
sis. However, this was unlikely to affect between-
group comparisons.
Prespecified Regression Analyses
Prespecified factors included in the multivariate 
model were age above 50 years (P<0.001) and in-
fradiaphragmatic disease (P = 0.24), whereas male 
sex (P = 0.32), systemic symptoms (P = 0.75), and a 
low albumin level (P = 0.54) were excluded. In the 
multivariate model including age, infradiaphrag-
matic involvement, and randomization group, no 
significant interaction was detected between the 
effects of the number of chemotherapy cycles and 
the radiation therapy dose.
Comparison of Groups 1 and 4
As shown in Figure 2, no significant difference 
in the rate of freedom from treatment failure was 
seen between groups 1 and 4 according to the 
stratified log-rank test (P = 0.79). The 5-year esti-
mate for the group difference was −1.6 percentage 
points (95% CI, −6.3 to 3.1), which is better than 
the noninferiority margin of −7 percentage points.
Discussion
The aim of the HD10 study was to determine 
whether fewer cycles of chemotherapy and lower 
doses of radiation therapy could be delivered while 
maintaining high rates of disease control in pa-
tients with early Hodgkin’s lymphoma and a fa-
vorable prognosis who were undergoing com-
bined-approach treatment programs. No differ-
ence in efficacy was noted between the two-cycle 
ABVD regimen and the four-cycle regimen when 
each was combined with involved-field radiation 
therapy. This was true for the primary end point, 
freedom from treatment failure at 5 years, as well 
as for all other efficacy end points, such as re-
sponse, overall survival, and progression-free sur-
vival. The results were robust with longer follow-
up (8 years). No differences were seen between 
the intention-to-treat and the per-protocol analy-
ses. With regard to radiation therapy, the rate of 
freedom from treatment failure at 5 years was 
93.4% (95% CI, 91.0 to 95.2) with 30 Gy of in-
volved-field radiation therapy and 92.9% (95% CI, 
90.4 to 94.8) with 20 Gy.
The results presented here show noninferior-
ity for both fewer cycles of chemotherapy and a 
lower dose of radiation, on the basis of a nonin-
feriority margin of 7 percentage points. However, 
confidence intervals were rather wide for differ-
ences in freedom from treatment failure and haz-
ard ratios. Although the 5-year estimate for the 
group difference between the most intensive treat-
ment and the least intensive treatment in this 
study was only 1.6 percentage points, a potential 
difference of 6.3 percentage points in favor of 
the more intensive treatment cannot be excluded 
and must be weighed against the reductions in 
acute and late toxicity, lower costs of treatment, 
and better quality of life associated with shorter 
and less intense treatment.
One of the key objectives in the treatment of 
Hodgkin’s lymphoma is to reduce the intensity of 
first-line therapy as much as possible while main-
taining tumor control. This is most relevant for 
early disease with a favorable prognosis, which 
accounts for about 30% of all cases of Hodgkin’s 
lymphoma,1 since overall survival rates are com-
promised by late treatment-related mortality.4-8 
In the HD10 study, two cycles of ABVD as well 
as 20 Gy of radiation resulted in reduced rates of 
acute toxicity. Overall, 51.7% of patients treated 
with four cycles of ABVD had grade III or IV tox-
icity, as compared with 33.2% of those receiving 
two cycles (P<0.001). The rates of acute toxicity 
(grade III or IV) were also higher among patients 
treated with 30 Gy of involved-field radiation 
therapy than among those receiving 20 Gy (8.7% 
vs. 2.9%, P<0.001). Although there were numerical 
differences between the radiation therapy groups 
with respect to secondary cancers (24 [4.1%] vs. 
31 [5.4%]), these findings were not significant and 
might have been due to chance. Clearly, longer 
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follow-up is needed to identify differences in long-
term toxicity, such as secondary neoplasia and 
severe organ damage, among different treatment 
approaches. Given that many of the late, fatal com-
plications of radiation therapy do not emerge until 
the second decade after treatment, our data can-
not speak to the effect of treatment on overall 
survival.
Since radiation therapy is associated with the 
development of secondary solid tumors 5 to 25 
years after initial treatment,4-8 some groups ad-
vocate the use of chemotherapy alone for patients 
with early-stage Hodgkin’s lymphoma. Usually, six 
cycles of ABVD are given, and there has been some 
controversy on this issue.15-19 For this group of 
patients, combined-approach treatment programs 
have provided superior tumor control when com-
pared directly with chemotherapy alone in some 
studies20-24 but not in others.15,19 Currently, com-
bined-approach treatment programs are widely 
used as the treatment of choice in early-stage 
Hodgkin’s lymphoma, and our study suggests that 
a shorter chemotherapy regimen with a lower 
radiation dose preserves a high level of disease 
control. With an overall survival rate of 95.1% at 
8 years, some patients may still be overtreated.
However, the established clinical risk factors, 
which are based on measures such as the Inter-
national Prognostic Score,25 currently do not allow 
identification of patients who can be cured with 
even less treatment. The use of positron-emission 
tomography (PET) might help to discriminate be-
tween patients at low risk and those at high risk, 
both early in the course of chemotherapy26 and 
after its completion.27 The potential effect of PET 
in patients with Hodgkin’s lymphoma has also 
been suggested in a number of retrospective, non-
randomized studies.28-30 Several ongoing trials 
are evaluating the role of PET in identifying pa-
tients with early Hodgkin’s lymphoma and a fa-
vorable prognosis who might not need additional 
radiation therapy after two cycles of ABVD (the 
German Hodgkin Study Group Hodgkin Disease 
16 [the current GHSG HD16] trial [ClinicalTrials 
.gov number, NCT00736320]) or after three cy-
cles of ABVD (the European Organization for Re-
search and Treatment of Cancer [EORTC H10F] 
trial [ClinicalTrials.gov number, NCT00433433] 
and others).
In summary, the HD10 trial showed that in 
patients with early-stage Hodgkin’s lymphoma and 
a favorable prognosis, treatment with two cycles 
of ABVD followed by 20 Gy of involved-field ra-
diation therapy is as effective as, and less toxic 
than, four cycles of ABVD followed by 30 Gy of 
involved-field radiation therapy.
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